Flu News Friday 11/12/21
Read the latest on influenza vaccines in this week’s roundup.
The Latest in Influenza Vaccines
1. Immune Response in Mice Immunized with Chimeric H1 Antigens Kotey, et al., Vaccines, October 15, 2021
This study explores new strategies to circumvent clinical and technical barriers in generating novel conserved antigenic epitopes for influenza vaccines. Researchers designed two resultant H1 HA-based chimeras comprising of conserved sequences (within several areas spanning the head and stalk regions) of H1 and H5 or H9 HAs to induce cross-reactive antibodies against A (H1N1) pdm09 virus. Further insight into cHA-induced immunity may, perhaps demonstrate its potential to improve antibody responses to influenza A viruses bearing similar conserved sites for the development of a universal influenza vaccine.
2. Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomized controlled trial
Shinde et al., The Lancet (Infectious Diseases), September/November 2021
Efforts to produce vaccine technologies avoidant of egg-adaptive antigenic changes are underway. This study – a phase 3 randomized controlled trial funded by Novavax–investigates clinical efficacy in a recombinant nanoparticle influenza vaccine candidate on inducting broadly cross-reactive antibodies and enhanced T-cell responses. Researchers aimed to show that the Matrix-M-adjuvanted quadrivalent nanoparticle influenza vaccine (qNIV) was immunologically non-inferior to a licensed, standard-dose quadrivalent inactivated influenza vaccine (IIV4) in older adults.
3. Next-Generation Computationally Designed Influenza Hemagglutinin Vaccines Protect against H5Nx Virus Infections
Nunez et al., Pathogens, October 20, 2021
Next-generation COBRA HA vaccines were designed to encompass the newly emerging viruses circulating in wild avian populations. In this study, H5N1 COBRA hemagglutinin (HA) sequences (human COBRA-2 HA), were constructed through layering of HA sequences from viruses isolated from humans collected between 2004–2007 using only clade 2 strains. These COBRA HA proteins, when expressed on the surface of virus-like particles (VLP), elicited protective immune responses in mice, ferrets, and non-human primates. However, these vaccines were not as effective at inducing neutralizing antibodies against newly circulating viruses. Therefore, COBRA HA-based vaccines were updated in order to elicit protective antibodies against the current circulating clades of H5Nx viruses.
4. Influence of the H1N1 influenza pandemic on the Humoral Immune Response to Seasonal Flu Vaccines
Hyesun Jang and Ted M. Ross, PLOS ONE, October 22, 2021
This systematic review investigates effectiveness of trivalent seasonal influenza virus vaccination during the 2009-2011 influenza seasons. Researchers hypothesized that the humoral response induced by the trivalent seasonal influenza virus vaccines used during the 2009/2010 and 2010/2011 influenza virus seasons was influenced by the introduction of novel H1 HA component, derived from pH1N1 virus. However, vaccine effectiveness of the 2009/2010 influenza virus vaccine was not fully evaluated and many participants showed significantly lower antibodies than the previous year.
5. Novel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness
Brett H. Pogostin and Kevin J. McHugh, Bioengineering 2021, October 24, 2021
This article describes several valuable approaches to improving immunity-conferring vaccine antigens for future infectious disease outbreaks. The use of modern adjuvants to improve vaccines against future pathogens is well documented but remains out of reach in the event of another outbreak. This perspective details the benefits of “ready-to-use adjuvant platforms” with the ability to promote a robust and protective immune response for a diverse set of antigens. Though many adjuvants are currently in preclinical development, slow adoption remains considerable due to safety concerns, regulatory hurdles, and issues with technology transfer.
6. Development of Molecular Clamp Stabilized Hemagglutinin Vaccines for Influenza A Viruses
McMillan et al., NPJ Vaccines, November 8, 2021
The emergence of an influenza virus pandemic is extremely high and has grown considerably due to the large reservoir of diverse influenza viruses found in animals and the co-circulation of many influenzas. A universal influenza vaccine equipped with rapid response technologies remains the best potential solution to counter a novel influenza outbreak. In this study, researchers demonstrate a modular trimerization domain known as the molecular clamp, to allow efficient production and purification of conformationally stabilized prefusion hemagglutinin (HA) from a diverse range of influenza A subtypes. These clamp-stabilized HA proteins provided robust protection from homologous virus challenge in mouse and ferret models and some cross protection against heterologous virus challenge and may provide proof-of-concept for clamp-stabilized HA vaccines as a tool for rapid response vaccine development against future influenza A virus pandemics.
7. Single Dose of Bivalent H5 and H7 Influenza Virus-Like Particle Protects Chickens Against Highly Pathogenic H5N1 and H7N9 Avian Influenza Viruses
Hu et al., Frontiers (Vet Science), November 11, 2021
Both H5N1 and H7N9 subtype avian influenza viruses cause enormous economic losses and pose considerable threats to public health. Bivalent vaccines against both two subtypes are more effective in control of H5N1 and H7N9 viruses in poultry and novel egg-independent vaccines are needed. H5 and H7 virus like particle (VLP) were generated in a baculovirus expression system and a bivalent H5+H7 VLP vaccine candidate was prepared by combining these two antigens. The exploration of bivalent VLP suggests bivalent H5+H7 VLP vaccine candidate may serve as a critical alternative for the traditional egg-based inactivated vaccines against H5N1 and H7N9 avian influenza virus infection in poultry.
8. Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages
Gravel et al., iScience 2021, November 19, 2021
A quarter of all seasonal influenza cases are caused by type B influenza virus (IBV) that also dominates periodically. In this study, researchers investigated a recombinant adenovirus vaccine carrying a synthetic HA2 representing the consensus sequence of all IBV hemagglutinins. The vaccine evaluated protection in mice from lethal challenges by IBV of both genetic lineages, demonstrating its breadth of protection. The findings suggest it could be worth further exploring this prototype for universal vaccine because of its considerable efficacy, safety, and breadth of protection.
Funding Opportunities & Announcements
Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed) (PAR-21-037) [Grant]
National Institute of Health, Due July 28, 2022
NIH Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional) [Grant]
National Institute of Health, Due January 5, 2022
Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer
NIH/National Cancer Institute, January 5, 2022
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) [Grant] National Institute of Health, Opens March 22, 2022
Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research [Exploratory/Developmental Grants Phase II]
National Institute of Health, National Cancer Institute, Opens March 22, 2022